These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

527 related articles for article (PubMed ID: 10526268)

  • 21. Apoptosis and cell-cycle regulatory proteins in colorectal carcinoma: relationship to tumour stage and patient survival.
    Elkablawy MA; Maxwell P; Williamson K; Anderson N; Hamilton PW
    J Pathol; 2001 Aug; 194(4):436-43. PubMed ID: 11523051
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The prognostic significance of p53 and bcl-2 expression in lung adenocarcinoma and its correlation with Ki-67 growth fraction.
    Ishida H; Irie K; Itoh T; Furukawa T; Tokunaga O
    Cancer; 1997 Sep; 80(6):1034-45. PubMed ID: 9305703
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Apoptosis and immunohistochemical bcl-2 expression in colorectal adenomas and carcinomas. Aspects of carcinogenesis and prognostic significance.
    Baretton GB; Diebold J; Christoforis G; Vogt M; Müller C; Dopfer K; Schneiderbanger K; Schmidt M; Löhrs U
    Cancer; 1996 Jan; 77(2):255-64. PubMed ID: 8625232
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunohistochemical expression of bcl-2 and p53 oncoproteins: correlation with Ki67 proliferation index and prognostic histopathologic parameters in colorectal neoplasia.
    Saleh HA; Jackson H; Banerjee M
    Appl Immunohistochem Mol Morphol; 2000 Sep; 8(3):175-82. PubMed ID: 10981868
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prognostic value of the expression of p53, bcl-2, and bax oncoproteins, and neovascularization in patients with radically resected non-small-cell lung cancer.
    Apolinario RM; van der Valk P; de Jong JS; Deville W; van Ark-Otte J; Dingemans AM; van Mourik JC; Postmus PE; Pinedo HM; Giaccone G
    J Clin Oncol; 1997 Jun; 15(6):2456-66. PubMed ID: 9196162
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Estimation of tumor stage and lymph node status in patients with colorectal adenocarcinoma using probabilistic neural networks and logistic regression.
    Singson RP; Alsabeh R; Geller SA; Marchevsky A
    Mod Pathol; 1999 May; 12(5):479-84. PubMed ID: 10349985
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Time-dependency of the prognostic effect of carcinoembryonic antigen and p53 protein in colorectal adenocarcinoma.
    Diez M; Pollan M; Müguerza JM; Gaspar MJ; Duce AM; Alvarez MJ; Ratia T; Herñandez P; Ruiz A; Granell J
    Cancer; 2000 Jan; 88(1):35-41. PubMed ID: 10618603
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparative analysis of prognostic significance of molecular markers of apoptosis with clinical stage and tumor differentiation in patients with colorectal cancer: a single institute experience.
    Ivanov K; Kolev N; Tonev A; Nikolova G; Krasnaliev I; Softova E; Tonchev A
    Hepatogastroenterology; 2009; 56(89):94-8. PubMed ID: 19453036
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The correlation between the immunostains for p53 and Ki67 with bcl-2 expression and classical prognostic factors in colorectal carcinomas.
    Gurzu S; Jung J; Mezei T; Pávai Z
    Rom J Morphol Embryol; 2007; 48(2):95-9. PubMed ID: 17641794
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinico-pathological correlation and prognostic significance of nuclear p53 protein in colorectal cancer. Colorectal Cancer Study Group of the University and Health Care District of Modena.
    Fante R; Di Gregorio C; Losi L; Roncucci L; Ponz de Leon M
    Ital J Gastroenterol; 1996 May; 28(4):205-10. PubMed ID: 8842835
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cytoplasmic accumulation of p53 protein: an independent prognostic indicator in colorectal adenocarcinomas.
    Bosari S; Viale G; Bossi P; Maggioni M; Coggi G; Murray JJ; Lee AK
    J Natl Cancer Inst; 1994 May; 86(9):681-7. PubMed ID: 8158699
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prognostic markers for colorectal cancer: expression of P53 and BCL2.
    Pereira H; Silva S; Julião R; Garcia P; Perpétua F
    World J Surg; 1997 Feb; 21(2):210-3. PubMed ID: 8995081
    [TBL] [Abstract][Full Text] [Related]  

  • 33. p53 and Ki-ras as prognostic factors for Dukes' stage B colorectal cancer.
    Bouzourene H; Gervaz P; Cerottini JP; Benhattar J; Chaubert P; Saraga E; Pampallona S; Bosman FT; Givel JC
    Eur J Cancer; 2000 May; 36(8):1008-15. PubMed ID: 10885605
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bio-pathological factors of prognostic value in colorectal adenocarcinomas.
    Mottolese M; Buglioli S; Piperno G; Sperduti I; Giannarelli D; D'Angelo C; Cosimelli M
    J Exp Clin Cancer Res; 2003 Dec; 22(4 Suppl):163-6. PubMed ID: 16767924
    [TBL] [Abstract][Full Text] [Related]  

  • 35. P53 and EGFR expression in colorectal cancer: a reappraisal of 'old' tissue markers in patients with long follow-up.
    Theodoropoulos GE; Karafoka E; Papailiou JG; Stamopoulos P; Zambirinis CP; Bramis K; Panoussopoulos SG; Leandros E; Bramis J
    Anticancer Res; 2009 Feb; 29(2):785-91. PubMed ID: 19331236
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Expression of p53, p21/waf, bcl-2, bax, Rb and Ki67 proteins in colorectal adenocarcinomas.
    Kanavaros P; Stefanaki K; Valassiadou K; Vlachonikolis J; Mavromanolakis M; Vlychou M; Kakolyris S; Gorgoulis V; Tzardi M; Georgoulias V
    Med Oncol; 1999 Apr; 16(1):23-30. PubMed ID: 10382939
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
    Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
    BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
    [TBL] [Abstract][Full Text] [Related]  

  • 38. c-erbB-2 oncoprotein is overexpressed in poorly vascularised squamous cell carcinomas of the head and neck, but is not associated with response to cytotoxic therapy or survival.
    Giatromanolaki A; Koukourakis MI; Sivridis E; Fountzilas G
    Anticancer Res; 2000; 20(2A):997-1004. PubMed ID: 10810387
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Molecular markers are predictors of recurrence and survival in patients with Dukes B and Dukes C colorectal adenocarcinoma.
    Bhatavdekar JM; Patel DD; Chikhlikar PR; Shah NG; Vora HH; Ghosh N; Trivedi TI
    Dis Colon Rectum; 2001 Apr; 44(4):523-33. PubMed ID: 11330579
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dukes B colorectal cancer: distinct genetic categories and clinical outcome based on proximal or distal tumor location.
    Gervaz P; Bouzourene H; Cerottini JP; Chaubert P; Benhattar J; Secic M; Wexner S; Givel JC; Belin B
    Dis Colon Rectum; 2001 Mar; 44(3):364-72; discussion 372-3. PubMed ID: 11289282
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.